Nebivolol Vs Atenolol and Placebo in Essential Hypertension: a Double-Blind Randomised Trial

Total Page:16

File Type:pdf, Size:1020Kb

Nebivolol Vs Atenolol and Placebo in Essential Hypertension: a Double-Blind Randomised Trial Journal of Human Hypertension (1998) 12, 135–140 1998 Stockton Press. All rights reserved 0950-9240/98 $12.00 ORIGINAL ARTICLE Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial L Van Nueten1, FR Taylor2 and JIS Robertson1 1Janssen Research Foundation, Beerse, Belgium; 2The Surgery, Hexton Road, Barton le Clay, Bedfordshire, UK A double-blind, randomised, parallel-group trial was cant falls in heart rate. Both active drugs were well toler- conducted in patients with essential hypertension in ated, nebivolol marginally more so. Nebivolol, a long- British general practices, of nebivolol 5 mg, atenolol acting, cardioselective, vasodilating beta-blocker which 50 mg, and placebo each given once daily. Both active acts partly via the l-arginine/nitric oxide mechanism, drugs, in comparison with placebo, caused highly sig- appears potentially valuable for the treatment of hyper- nificant and similar reductions in systolic and diastolic tension. pressures without orthostatic effect, and small signifi- Keywords: nitric oxide; quality of life; side effects Introduction daily were begun. After 4 weeks of this single-blind placebo run-in, those with a sitting diastolic press- Nebivolol is a highly cardioselective beta-blocking ure of at least 95 mm Hg and at most 115 mm Hg agent devoid of intrinsic sympathomimetic activity, could enter the trial proper. A previous dose- with vasodilating properties and a prolonged action; response trial of nebivolol had shown that 5 mg it acts in part via the l-arginine/nitric oxide path- once daily in hypertensive patients controlled blood way. At similar anti-hypertensive doses, nebivolol pressure (BP) over 24 h; no additional effect was has been found to exert less beta-1 blockade than do seen with 10 mg.10 Likewise, atenolol 50 mg once standard beta-blockers, as judged by the extent of daily had earlier been found to be as effective as reduction of exercise-induced tachycardia.1–9 This 100 mg.11 Thus the doses of active drugs used were paper reports a double-blind randomised trial of once-daily nebivolol compared with once-daily nebivolol 5 mg and atenolol 50 mg. Patients were atenolol, a well established cardioselective beta- randomised via a computer-generated list to receive, blocker and placebo, in essential hypertension. double-blind, once-daily placebo, or nebivolol 5 mg, or atenolol 50 mg, for the trial duration of 1 month, further visits being scheduled at 2 weeks and at the Patients and methods end of this time. If after 2 weeks of the double-blind Ͼ The trial was conducted in patients under primary treatment the diastolic pressure was 120 mm Hg, Ͼ medical care (general practice) in Britain. Male and or the systolic 220 mm Hg, patients were with- female ambulatory subjects, between the ages of 18 drawn and considered as non-responders. Patients and 71 years, with mild-to-moderate essential could also withdraw at any time should they wish; hypertension, were eligible; those previously or for any reason at the discretion of the investigator, untreated, or who had responded poorly or were or if a serious adverse event occurred. intolerant of previous treatment, could be recruited. All trial medication consisted of tablets identical Exclusion criteria are listed in Table 1. Those in appearance and taste. Patients were instructed to entering were required to give informed consent. At take one tablet once daily at breakfast, except on the the screening visit, initial assessments were perfor- occasion of clinic visits, when medication was omit- med, candidate patients were asked to discontinue ted until after BP had been taken. Thus the BP any current anti-hypertensive drugs within the next values reported (Figures 1–4) are those obtained 23– 2 weeks, while single-blind placebo tablets once 25 h after dosing. Drugs that might interfere with the anti-hypertensive effect of the trial medication were not allowed (see Table 1). Other medications were Correspondence: Dr L Van Nueten, Janssen Research Foundation, permitted as needed provided they remained International Clinical R&D, Internal Medicine, Turnhoutseweg unchanged during the trial; short-term treatment of 30, 2340 Beerse, Belgium Received 20 June 1997; revised 1 October 1997; accepted 10 intercurrent illness was also allowed. Compliance October 1997 was assessed by tablet count at the end of the Nebivolol and atenolol in essential hypertension L Van Nueten et al 136 Table 1 Exclusion criteria ț secondary hypertension, or malignant hypertension (retinal haemorrhage, exudates or papillary oedema) ț asthma or chronic obstructive airway disease ț bradycardia (less than 60 beats per minute at rest) ț atrial fibrillation or recurrent tachyarrhythmia requiring antiarrhythmic therapy ț insulin dependent diabetes ț history of sensitivity or severe adverse reaction to beta-blockers ț myocardial infarction or cerebrovascular accident within the last 6 months ț heart failure requiring treatment, or valvular disease of haemodynamic significance ț severe renal or hepatic disease (urine protein Ͼ trace, creatinine Ͼ 2.2 mg/dl or Ͼ 200 Tmol/l, ASAT and/or ALAT greater than twice the upper normal limit) ț (possible) pregnancy or nursing ț any concurrent condition that could, according to the investigator, jeopardise participant adherence to the protocol or ability to complete the trial (eg, alcohol or drug abuse, disabling or terminal illness, personality or mental disorders) ț concurrent therapy with medications that could affect blood pressure (therapy with tricyclic antidepressants drugs or MAO inhibitors; corticosteroids or non-steroidal anti-inflammatory drugs, if used regularly; hormonal contraceptives) ț investigational drug treatment within the past 120 days ț predictable lack of co-operation Figure 1 Diastolic blood pressure, sitting: (means ± s.e.m.). W = Week of trial. The number of patients contributing to each value is given. (– – –) placebo; (-------) atenolol; (——) nebivolol. double-blind trial period. Major dietary changes, eg, taneously, or if recalled in response to the standard for weight reduction or salt restriction, were not per- question, ‘Has treatment upset you in any way?’. mitted during the trial. Positive experiences were recorded if reported spon- Systolic and diastolic pressures were recorded, taneously, or in response to the standard question, using a random-zero sphygmomanometer, taking ‘Did you experience any beneficial effect from treat- Korotkoff phases 1 and 5, respectively. In each ment?’. A quality of life questionnaire comprising patient, measurements were made by the same 91 questions was completed by a subset of patients investigator or member of the investigator’s staff, in at the end of the 4-week double-blind period. A 12- the same room and at the same time of day, prefer- lead electrocardiogram was recorded at screening, at ably in the morning. At the first visit BP was determ- the end of the placebo run-in, and at the end of the ined in both arms; if a difference of Ͼ4 mm Hg was double-blind treatment period. Routine haematolog- found, the arm with the higher pressure was used ical, biochemical, and urine tests were performed at throughout, otherwise the right arm was always screening, at the end of the placebo run-in, and at employed. The sphygmomanometer cuff was at least the end of the double-blind treatment period. 30 cm long and 13 cm wide; if the arm circumfer- On the assumption that a difference in supine ence exceeded 34 cm, an appropriately larger cuff diastolic pressure by a mean ± s.d. of 5 mm Hg ± was used. Sitting BP was taken after the patient had 11.5 would occur between placebo and at least one rested for 5 min; standing pressure after 2 min of of the other treatment groups, it was calculated that standing. Heart rate was counted sitting and stand- a total of 414 patients (138 per treatment group) ing. At each visit patients were weighed partially would be needed to detect the difference with a 5% clothed. two-tailed significance and 95% power. Adverse events were noted if mentioned spon- The primary pre-declared index variable was sit- Nebivolol and atenolol in essential hypertension L Van Nueten et al 137 Figure 2 Diastolic blood pressure, standing: (means ± s.e.m.). W = Week of trial. The number of patients contributing to each value is given. (– – –) placebo; (--------) atenolol; (——) nebivolol. Figure 3 Systolic blood pressure, sitting: (means ± s.e.m.). W = Week of trial. The number of patients contributing to each value is given. (– – –) placebo; (--------) atenolol; (——) nebivolol. ting diastolic pressure at ‘trough’ drug level, 23–25 h decrease in sitting diastolic pressure at trough drug from the previous intake of medication, using the level to 90 mm Hg or below. The ␹2 test was used to last available reading in each patient (end-point), detect between-group differences for the percentages whether or not that patient completed the intended of responders. The quality of life questionnaire was full trial duration. An ‘intent to treat’ analysis was evaluated descriptively and by non-parametric test performed, that is, all randomised patients, regard- (Wilcoxon–Mann–Whitney U-test). less of their compliance with the protocol, were included. Treatment effects were evaluated at a two- Results tailed 5% significance level by means of a one-way analysis of variance. If the overall comparison was A total of 366 patients entered the run-in period, ie, significant, multiple comparisons were made by slightly fewer than were intended from the above Dunnett’s t-test to assess differences between nebiv- statistical considerations. Of these, two dropped out olol and placebo and between nebivolol and ateno- before randomisation. Of the remainder, 119 were lol. Response rate (normalisation) was defined as a allocated to nebivolol, 121 to atenolol and 124 to Nebivolol and atenolol in essential hypertension L Van Nueten et al 138 Figure 4 Systolic blood pressure, standing: (means ± s.e.m.).
Recommended publications
  • M2021: Pharmacogenetic Testing
    Pharmacogenetic Testing Policy Number: AHS – M2021 – Pharmacogenetic Prior Policy Name and Number, as applicable: Testing • M2021 – Cytochrome P450 Initial Presentation Date: 06/16/2021 Revision Date: N/A I. Policy Description Pharmacogenetics is defined as the study of variability in drug response due to heredity (Nebert, 1999). Cytochrome (CYP) P450 enzymes are a class of enzymes essential in the synthesis and breakdown metabolism of various molecules and chemicals. Found primarily in the liver, these enzymes are also essential for the metabolism of many medications. CYP P450 are essential to produce many biochemical building blocks, such as cholesterol, fatty acids, and bile acids. Additional cytochrome P450 are involved in the metabolism of drugs, carcinogens, and internal substances, such as toxins formed within cells. Mutations in CYP P450 genes can result in the inability to properly metabolize medications and other substances, leading to increased levels of toxic substances in the body. Approximately 58 CYP genes are in humans (Bains, 2013; Tantisira & Weiss, 2019). Thiopurine methyltransferase (TPMT) is an enzyme that methylates azathioprine, mercaptopurine and thioguanine into active thioguanine nucleotide metabolites. Azathioprine and mercaptopurine are used for treatment of nonmalignant immunologic disorders; mercaptopurine is used for treatment of lymphoid malignancies; and thioguanine is used for treatment of myeloid leukemias (Relling et al., 2011). Dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, is a rate-limiting enzyme responsible for fluoropyrimidine catabolism. The fluoropyrimidines (5-fluorouracil and capecitabine) are drugs used in the treatment of solid tumors, such as colorectal, breast, and aerodigestive tract tumors (Amstutz et al., 2018). A variety of cell surface proteins, such as antigen-presenting molecules and other proteins, are encoded by the human leukocyte antigen genes (HLAs).
    [Show full text]
  • Supporting Information a Analysed Substances
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 List of contents: Tab. A1 Detailed list and classification of analysed substances. Tab. A2 List of selected MS/MS parameters for the analytes. Tab. A1 Detailed list and classification of analysed substances. drug of therapeutic doping agent analytical standard substance abuse drug (WADA class)* supplier (+\-)-amphetamine ✓ ✓ S6 stimulants LGC (+\-)-methamphetamine ✓ S6 stimulants LGC (+\-)-3,4-methylenedioxymethamphetamine (MDMA) ✓ S6 stimulants LGC methylhexanamine (4-methylhexan-2-amine, DMAA) S6 stimulants Sigma cocaine ✓ ✓ S6 stimulants LGC methylphenidate ✓ ✓ S6 stimulants LGC nikethamide (N,N-diethylnicotinamide) ✓ S6 stimulants Aldrich strychnine S6 stimulants Sigma (-)-Δ9-tetrahydrocannabinol (THC) ✓ ✓ S8 cannabinoids LGC (-)-11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) S8 cannabinoids LGC morphine ✓ ✓ S7 narcotics LGC heroin (diacetylmorphine) ✓ ✓ S7 narcotics LGC hydrocodone ✓ ✓ Cerillant® oxycodone ✓ ✓ S7 narcotics LGC (+\-)-methadone ✓ ✓ S7 narcotics Cerillant® buprenorphine ✓ ✓ S7 narcotics Cerillant® fentanyl ✓ ✓ S7 narcotics LGC ketamine ✓ ✓ LGC phencyclidine (PCP) ✓ S0 non-approved substances LGC lysergic acid diethylamide (LSD) ✓ S0 non-approved substances LGC psilocybin ✓ S0 non-approved substances Cerillant® alprazolam ✓ ✓ LGC clonazepam ✓ ✓ Cerillant® flunitrazepam ✓ ✓ LGC zolpidem ✓ ✓ LGC VETRANAL™ boldenone (Δ1-testosterone / 1-dehydrotestosterone) ✓ S1 anabolic agents (Sigma-Aldrich)
    [Show full text]
  • 667783-Atenolol (ACC-UK)06-16-SPC-PIL
    Artwork No. - Colours Used Customer Accord Pantone Black Description Atenolol Market UK Language English Size 170 x 550 mm PIL Min. Font Size 9.5 Version No. 13 (Page 1 of 2) (06-16-Atenolol SPC) Date 07_05_16 (Atenolol (ACC-UK)06-16-SPC-PIL) Prepared By Checked By Approved By Regulatory Affairs Regulatory Affairs Quality Assurance You must consult your doctor if you are If you forget to take Atenolol Tablets 6. Contents of the pack and other planning to combine Atenolol tablets with the If you forget to take a dose of the Atenolol information medicines listed below: Tablet, take it as soon as you remember, PACKAGE LEAFLET: INFORMATION FOR • Clonidine (for high blood pressure or unless it is time for your next dose. What Atenolol Tablet contains THE USER migraine). If you are taking clonidine and Do not take a double dose to make up for a • The active ingredient is Atenolol. Atenolol 25 mg Tablets Atenolol tablets together, do not stop taking forgotten dose. • The other ingredients are Heavy clonidine unless your doctor tells you to do Magnesium Carbonate, Maize Starch, Atenolol 50 mg Tablets so. If you have to stop taking clonidine, your If you stop taking Atenolol Tablets Sodium Lauryl Sulphate, Gelatin, doctor will give you careful instructions Do not stop taking Atenolol Tablets without Magnesium Stearate, Microcrystalline Atenolol 100 mg Tablets about how to do it. talking to your doctor. In some cases, you may Cellulose and Purified Talc. (Atenolol) • Verapamil, diltiazem and nifedipine (for high need to stop taking it gradually over 7-14 days blood pressure or chest pain).
    [Show full text]
  • Drugs-Biologicals FORMULARY for INTERNET PAGE 12 26 18
    AVG ITEM Average Patient Item Charge Code Description BIL AWP /pkg COST Price 25000041 SODIUM and POTASSIUM BICARBONATE TBEF UD $3.61 $0.12 $1.00 25000054 GLIMEPIRIDE TAB 1 MG UD $8.25 $0.11 $1.30 25000086 amLODIPine TAB 5 MG UD $8.65 $0.06 $1.00 25000087 AMMONIA AROMATIC SOLN 15 % (W/V) UD $3.53 $0.17 $1.00 25000090 AMOXICILLIN CAP 500 MG UD $20.12 $0.19 $1.00 25000102 ABACAVIR TAB 300 MG UD $507.10 $8.45 $16.90 25000103 ACAMPROSATE TBEC 333 MG UD $182.38 $0.80 $1.76 25000104 ACARBOSE TAB 25 MG UD $16.70 $0.27 $1.00 25000106 ACETAMINOPHEN SUPP 120 MG UD $5.09 $0.42 $1.00 25000108 ACETAMINOPHEN SUPP 325 MG UD $4.91 $0.44 $1.00 25000109 ACETAMINOPHEN TAB 325 MG UD $12.39 $0.02 $1.00 25000111 ACETAMINOPHEN TAB 500 MG UD $2.34 $0.02 $1.00 25000112 ACETAMINOPHEN SUPP 650 MG UD $3.83 $0.17 $1.00 25000113 ACETAMINOPHEN SOLN 650 MG/20.3 ML UD $75.74 $0.48 $1.22 25000117 ACETAMINOPHEN-CODEINE TAB 300-30 MG UD $12.41 $0.09 $1.00 25000121 ACETYLCYSTEINE SOLN 200 MG/ML (20 %) UD $18.18 $7.66 $15.32 25000140 ALBUTEROL SULFATE NEBU 2.5MG/3ML (0.083 %) UD $8.58 $0.29 $1.00 25000147 ALLOPURINOL TAB 100 MG UD $18.45 $0.12 $1.00 25000150 ALPRAZolam TAB 0.25 MG UD $8.87 $0.09 $1.00 25000151 ALPRAZolam TAB 0.5 MG UD $4.16 $0.04 $1.00 25000182 AMIODARONE TAB 200 MG UD $15.70 $0.20 $1.00 25000184 AMITRIPTYLINE TAB 10 MG UD $8.73 $0.06 $1.00 25000186 AMITRIPTYLINE TAB 25 MG UD $17.46 $0.08 $1.00 25000188 AMITRIPTYLINE TAB 50 MG UD $34.90 $0.16 $1.00 25000205 HYDROCORTISONE ACETATE SUPP 25 MG UD $127.30 $5.75 $11.50 25000206 HEMORRHOIDAL SUPPOSITORY SUPP 0.25
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Pms-ATENOLOL Atenolol Tablets, BP 25 Mg, 50 Mg and 100 Mg
    - PRODUCT MONOGRAPH Pr pms-ATENOLOL Atenolol Tablets, BP 25 mg, 50 mg and 100 mg Beta-adrenergic receptor blocking agent PHARMASCIENCE INC. Date of Revision: 6111 Royalmount Ave., Suite 100 November 3, 2017 Montreal, Quebec H4P 2T4 www.pharmascience.com Submission Control No: 201217 PRODUCT MONOGRAPH NAME OF DRUG Prpms-ATENOLOL Atenolol Tablets, BP 25 mg, 50 mg and 100 mg THERAPEUTIC CLASSIFICATION Beta-adrenergic receptor blocking agent ACTIONS AND CLINICAL PHARMACOLOGY Atenolol is a beta1-selective, beta adrenergic blocking agent, devoid of membrane stabilizing or intrinsic sympathomimetic (partial agonist) activities. It is a racemic mixture and the beta1 properties reside in the S (-) enantiomer. Beta1-selectivity decreases with increasing dose. The mechanism of the antihypertensive effect has not been established. Among the factors that may be involved are: a) competitive ability to antagonize catecholamine-induced tachycardia at the beta-receptor sites in the heart, thus decreasing cardiac output b) inhibition of renin release by the kidneys c) inhibition of the vasomotor centres The mechanism of the anti-anginal effect is also uncertain. An important factor may be the reduction of myocardial oxygen requirements by blocking catecholamine-induced increases in heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. In man atenolol reduces both isoproterenol- and exercise-induced increases in heart rate over the dose range of 50 to 200 mg. At an oral dose of 100 mg the beta1 blocking effects persist for at least 24 hours; the reduction in exercise-induced heart rate increase being about 32% and 13%, 2 and 24 hours after dosing, respectively.
    [Show full text]
  • Migraine Headache Prophylaxis Hien Ha, Pharmd, and Annika Gonzalez, MD, Christus Santa Rosa Family Medicine Residency Program, San Antonio, Texas
    Migraine Headache Prophylaxis Hien Ha, PharmD, and Annika Gonzalez, MD, Christus Santa Rosa Family Medicine Residency Program, San Antonio, Texas Migraines impose significant health and financial burdens. Approximately 38% of patients with episodic migraines would benefit from preventive therapy, but less than 13% take prophylactic medications. Preventive medication therapy reduces migraine frequency, severity, and headache-related distress. Preventive therapy may also improve quality of life and prevent the progression to chronic migraines. Some indications for preventive therapy include four or more headaches a month, eight or more headache days a month, debilitating headaches, and medication- overuse headaches. Identifying and managing environmental, dietary, and behavioral triggers are useful strategies for preventing migraines. First-line med- ications established as effective based on clinical evidence include divalproex, topiramate, metoprolol, propranolol, and timolol. Medications such as ami- triptyline, venlafaxine, atenolol, and nadolol are probably effective but should be second-line therapy. There is limited evidence for nebivolol, bisoprolol, pindolol, carbamazepine, gabapentin, fluoxetine, nicardipine, verapamil, nimodipine, nifedipine, lisinopril, and candesartan. Acebutolol, oxcarbazepine, lamotrigine, and telmisartan are ineffective. Newer agents target calcitonin gene-related peptide pain transmission in the migraine pain pathway and have recently received approval from the U.S. Food and Drug Administration; ​​​how- ever, more studies of long-term effectiveness and adverse effects are needed. The complementary treatments petasites, feverfew, magnesium, and riboflavin are probably effective. Nonpharmacologic therapies such as relaxation training, thermal biofeedback combined with relaxation training, electromyographic feedback, and cognitive behavior therapy also have good evidence to support their use in migraine prevention. (Am Fam Physician. 2019; 99(1):17-24.
    [Show full text]
  • Reference ID: 3940505 FULL PRESCRIBING INFORMATION
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Do not co-administer aliskiren with BYVALSON in patients with These highlights do not include all the information needed to use diabetes. (4) BYVALSON safely and effectively. See full prescribing information for -----------------------WARNINGS AND PRECAUTIONS-----------------------­ BYVALSON. • Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue. (5.3) BYVALSON (nebivolol and valsartan) tablets, for oral use • Diabetes: Monitor glucose as β-blockers may mask symptoms of Initial U.S. Approval: 2016 hypoglycemia. (5.7) • Monitor renal function and potassium in susceptible patients. (5.11) WARNING: FETAL TOXICITY ------------------------------ADVERSE REACTIONS------------------------------­ See full prescribing information for complete boxed warning. No adverse reactions were observed more frequently on BYVALSON than on • When pregnancy is detected, discontinue BYVALSON as soon as placebo. (6.1) possible (5.1, 8.1) • Drugs, including BYVALSON, that act directly on the renin­ To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1­ angiotensin system can cause injury and death to the developing 800-272-5525or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. fetus. (5.1, 8.1) ------------------------------DRUG INTERACTIONS------------------------------­ • CYP2D6 enzyme inhibitors increase nebivolol levels. (7) ----------------------------INDICATIONS AND USAGE--------------------------­ • Reserpine or clonidine may produce excessive reduction of sympathetic BYVALSON is a beta adrenergic blocker and an angiotensin II receptor activity. (7) blocker (ARB) indicated for the treatment of hypertension, to lower blood • Digitalis glycosides increase the risk of bradycardia. (7) pressure. Lowering blood pressure reduces the risk of fatal and nonfatal • Verapamil- or diltiazem-type calcium channel blockers may cause cardiovascular events, primarily strokes and myocardial infarctions.
    [Show full text]
  • Comparative Effects of Nebivolol and Atenolol on Blood Pressure and Insulin Sensitivity in Hypertensive Subjects with Type II Diabetes
    Journal of Human Hypertension (1997) 11, 753–757 1997 Stockton Press. All rights reserved 0950-9240/97 $12.00 ORIGINAL ARTICLE Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes R Fogari1, A Zoppi1, P Lazzari1, A Mugellini1, P Lusardi1, P Preti1, L Van Nueten2 and C Vertommen2 1Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; 2Janssen Research Foundation, Beerse, Belgium The aim of this double-blind, parallel group study was to rate during the last 60 min of clamp and total glucose compare the effects of nebivolol and atenolol on blood requirements were evaluated. Nebivolol 5 mg once daily pressure (BP) and insulin sensitivity in hypertensive was of an equivalent efficacy as atenolol 50 mg once patients with type II, non-insulin dependent diabetes daily at reducing supine and standing systolic and dias- mellitus (NIDDM). After a 4-week run-in period on pla- tolic BP values. Neither b-blocker adversely affected cebo, 30 patients (14 males and 16 females) aged 43 to carbohydrate metabolism in terms of insulin sensitivity, 69 years, with stable NIDDM and mild to moderate whole body glucose utilization, HbA1c and 24-h urinary hypertension (DBP >95 and ,116 mm Hg) were random- C-peptide excretion. No significant changes in choles- ised to receive either nebivolol 5 mg or atenolol 50 mg, terol (total, high density and low density lipoprotein) both administered once daily for 6 months. At the end and triglycerides plasma levels were observed with both of the placebo and the active treatment periods, supine b-blockers.
    [Show full text]
  • Compositions Comprising Nebivolol
    (19) TZZ ZZ__T (11) EP 2 808 015 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.12.2014 Bulletin 2014/49 A61K 31/34 (2006.01) A61K 31/502 (2006.01) A61K 31/353 (2006.01) A61P 9/00 (2006.01) (21) Application number: 14002458.9 (22) Date of filing: 16.11.2005 (84) Designated Contracting States: • O’Donnell, John AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Morgantown, WV 26505 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Bottini, Peter Bruce SK TR Morgantown, WV 26505 (US) • Mason, Preston (30) Priority: 31.05.2005 US 141235 Morgantown, WV 26504 (US) 10.11.2005 US 272562 • Shaw, Andrew Preston 15.11.2005 US 273992 Morgantown, WV 26504 (US) (62) Document number(s) of the earlier application(s) in (74) Representative: Samson & Partner accordance with Art. 76 EPC: Widenmayerstraße 5 09015249.7 / 2 174 658 80538 München (DE) 05848185.4 / 1 890 691 Remarks: (71) Applicant: MYLAN LABORATORIES, INC This application was filed on 16-07-2014 as a Morgantown, NV 26504 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: • Davis, Eric Morgantown, WV 26508 (US) (54) Compositions comprising nebivolol (57) The active ingredients of the pharmaceutical composition described consist of nebivolol, one or more ACE inhibitors and one or more ARB. EP 2 808 015 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 808 015 A1 Description [0001] This application is a continuation-in-part of application Ser.
    [Show full text]
  • Compendial Deferrals for USP41-NF36 1S
    Compendial Deferrals for USP41-NF36 1S Category Monograph Title Monograph Section Scientific Liaison {Emollient} Sodium Lauroyl Sarcosinate, {Emulsifying Agent} Sodium Lauroyl Revision USP AND NF EXCIPIENTS, LISTED BY CATEGORY PF 42(2) Pg. ONLINE Sarcosinate, {Chaotropic Agent} Hong Wang Introduction, 1. INTRODUCTION, 2. GENERAL QUALITY TESTS FOR INHALATION DRUG <5> INHALATION AND NASAL DRUG PRODUCTS GENERAL INFORMATION AND PRODUCTS, 3. GENERAL QUALITY TESTS FOR NASAL DRUG PRODUCTS, 4. Revision PRODUCT QUALITY TESTS PF 43(1) Pg. ONLINE DESCRIPTION OF PRODUCT QUALITY TESTS Kahkashan Zaidi Bendamustine Hydrochloride, Ropivacaine, Bortezomib, Sodium Lauroyl Sarcosinate, Epinastine Hydrochloride, Imipramine Hydrochloride, Carglumic Acid, Iloperidone, Benzphetamine Hydrochloride, Deferasirox, Eletriptan Hydrobromide, Milnacipran New DESCRIPTION AND SOLUBILITY PF 43(1) Pg. ONLINE Hydrochloride, Nebivolol Hydrochloride Feiwen Mao Title, INTRODUCTION/Introduction, PROCEDURE/Identification, PROCEDURE/Enumeration, PERFORMANCE TESTS/, CONTAMINANTS/Introduction, CONTAMINANTS/Listeria, ADDITIONAL REQUIREMENTS/Storage, ADDITIONAL New <64> PROBIOTIC TESTS - GENERAL PF 43(2) Pg. ONLINE REQUIREMENTS/Labeling, ??UNKNOWN??/Introduction Seong Jae Yoo Title, Introduction, INTRODUCTION, CHARACTERISTICS, IDENTIFICATION, TEST PROCEDURES, BIOLOGICAL TESTS, PHYSICOCHEMICAL TESTS, FUNCTIONALITY New <381> ELASTOMERIC CLOSURES FOR INJECTIONS PF 43(3) Pg. ONLINE TESTS, 1. INTRODUCTION, 2. SCOPE, 3. SPECIFICATIONS, 4. TEST METHODS Desmond Hunt Title, 1. INTRODUCTION,
    [Show full text]
  • BYSTOLIC Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Patients with severe hepatic impairment (Child-Pugh >B) These highlights do not include all the information needed to (4) use BYSTOLIC safely and effectively. See full prescribing • Hypersensitive to any component of this product (4) information for BYSTOLIC. -------------WARNINGS AND PRECAUTIONS---------- BYSTOLIC® (nebivolol) tablets, for oral use • Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue. (5.1) Initial U.S. Approval: 2007 • Diabetes: Monitor glucose as β-blockers may mask symptoms of hypoglycemia. (5.5) ------------RECENT MAJOR CHANGES------------------­ Indications and Usage (1.1) 12/2011 -----------------ADVERSE REACTIONS----------------- Most common adverse reactions (6.1): --------------INDICATIONS AND USAGE--------------- • Headache, fatigue BYSTOLIC is a beta-adrenergic blocking agent indicated for To report SUSPECTED ADVERSE REACTIONS, Contact the treatment of hypertension, to lower blood pressure. Forest Laboratories, Inc. at 1-800-678-1605 or FDA at Lowering blood pressure reduces the risk of fatal and nonfatal 1-800-FDA-1088 or www.fda.gov/medwatch. cardiovascular events, primarily strokes and myocardial infarctions. (1.1) ----------------DRUG INTERACTIONS------------------ • CYP2D6 enzyme inhibitors may increase nebivolol levels. ------------DOSAGE AND ADMINISTRATION---------- (7.1) Can be taken with and without food. Individualize to the • Reserpine or clonidine may produce excessive reduction needs of the patient and monitor during up-titration. (2) of sympathetic activity. (7.2) • Hypertension: Most patients start at 5 mg once daily. • Both digitalis glycosides and β-blockers slow Dose can be increased at 2-week intervals up to 40 mg. atrioventricular conduction and decrease heart rate. (2.1) Concomitant use can increase the risk of bradycardia.
    [Show full text]